UY27823A1 - Nueva formulación para la administración parenteral de un bloqueante del canal del na - Google Patents

Nueva formulación para la administración parenteral de un bloqueante del canal del na

Info

Publication number
UY27823A1
UY27823A1 UY27823A UY27823A UY27823A1 UY 27823 A1 UY27823 A1 UY 27823A1 UY 27823 A UY27823 A UY 27823A UY 27823 A UY27823 A UY 27823A UY 27823 A1 UY27823 A1 UY 27823A1
Authority
UY
Uruguay
Prior art keywords
parenteral administration
del
blocker
canal
new formulation
Prior art date
Application number
UY27823A
Other languages
English (en)
Spanish (es)
Inventor
Dr Bernd Kruss
Annerose Mauz
Karin Ruehr
Jean Marie Stassen
Claus Veit
Dr Klaus Wagner
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27823A1 publication Critical patent/UY27823A1/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY27823A 2002-05-29 2003-05-27 Nueva formulación para la administración parenteral de un bloqueante del canal del na UY27823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
UY27823A1 true UY27823A1 (es) 2003-12-31

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27823A UY27823A1 (es) 2002-05-29 2003-05-27 Nueva formulación para la administración parenteral de un bloqueante del canal del na

Country Status (12)

Country Link
EP (1) EP1511517B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005527615A (cg-RX-API-DMAC7.html)
AR (1) AR040134A1 (cg-RX-API-DMAC7.html)
AT (1) ATE373492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003237664A1 (cg-RX-API-DMAC7.html)
CA (1) CA2487150A1 (cg-RX-API-DMAC7.html)
DE (2) DE10223783A1 (cg-RX-API-DMAC7.html)
ES (1) ES2294295T3 (cg-RX-API-DMAC7.html)
PE (1) PE20040066A1 (cg-RX-API-DMAC7.html)
TW (1) TW200400029A (cg-RX-API-DMAC7.html)
UY (1) UY27823A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003099336A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
DE50308227D1 (de) 2007-10-31
DE10223783A1 (de) 2003-12-11
EP1511517A1 (de) 2005-03-09
ES2294295T3 (es) 2008-04-01
JP2005527615A (ja) 2005-09-15
AU2003237664A1 (en) 2003-12-12
EP1511517B1 (de) 2007-09-19
PE20040066A1 (es) 2004-03-22
ATE373492T1 (de) 2007-10-15
WO2003099336A1 (de) 2003-12-04
AR040134A1 (es) 2005-03-16
CA2487150A1 (en) 2003-12-04
TW200400029A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
UY26780A1 (es) Cicloalquil avb3 antagonistas
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ITRM20030355A1 (it) Composti ad attivita' citotossica derivati della combretastatina.
UY28422A1 (es) Sistemas emulsionantes que contienen derivados de azetidina
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.
NO20064808L (no) Orale matrixformuleringer med licarbazepin
UY27823A1 (es) Nueva formulación para la administración parenteral de un bloqueante del canal del na
NO20064783L (no) Opplosningstabeletter med licarbazepin
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
CR7648A (es) Microcapsulas para la liberacion retardada y controlada del perindropil
PT1052995E (pt) Composicao farmaceutica para a administracao por via nasal de tiocolchicosido
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh
BR0105939A (pt) Método para a produção de derivados de citidina
AR046808A1 (es) Composicion farmaceutica para la administracion de piribedil por via nasal
GT199800008A (es) Procedimiento para la preparacion de un derivado de tetrahidropiridina.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150223